Testosterone

Overview

Testosterone is a medication and naturally occurring steroid hormone. It is used to treat male hypogonadism, gender dysphoria, and certain types of breast cancer. It may also be used with the intent to increase athletic ability in the form of doping. It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. Testosterone can be administered through several different routes, including topical gels or patches, nasal sprays, subdermal implants, or tablets dissolved inside the mouth. Testosterone therapy has been associated with improvements in depressive symptoms (especially in hypogonadal men), increased exercise capacity and muscle strength in men with chronic heart failure, and male contraception effectiveness.[1][2][3] WP

Common side effects of testosterone include acne, swelling, and breast enlargement in men. Serious side effects may include liver toxicity, heart disease, and behavioral changes. Women and children who are exposed may develop masculinization. It is recommended that individuals with prostate cancer should not use the medication. It can cause harm to the baby if used during pregnancy or breastfeeding. Testosterone is in the androgen family of medications.[1] WP

Testosterone was first isolated in 1935, and approved for medical use in 1939. Rates of use have increased three times in the United States between 2001 and 2011. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 119th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[1][4–9] WP

Uses, dosage and effects

Medical uses

The primary use of testosterone is the treatment of males with too little or no natural testosterone production, also termed male hypogonadism or hypoandrogenism (androgen deficiency). This treatment is referred to as hormone replacement therapy (HRT), or alternatively, and more specifically, as testosterone replacement therapy (TRT) or androgen replacement therapy (ART). It is used to maintain serum testosterone levels in the normal male range. Decline of testosterone production with age has led to interest in testosterone supplementation.[10][11] WP

A 2020 guideline from the American College of Physicians supports the discussion of testosterone in adult men with age-related low levels of testosterone who have sexual dysfunction. They recommend yearly evaluation regarding possible improvement and, if none, to discontinue testosterone; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar. Testosterone treatment for reasons other than possible improvement of sexual dysfunction may not be recommended.[12][13] WP

Deficiency

Testosterone deficiency (also termed hypotestosteronism or hypotestosteronemia) is an abnormally low testosterone production. It may occur because of testicular dysfunction (primary hypogonadism) or hypothalamic–pituitary dysfunction (secondary hypogonadism) and may be congenital or acquired.[14] WP

Low levels due to aging

Testosterone levels may decline gradually with age. The United States Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone supplement have been established for low testosterone levels due to aging. The FDA has required that labels on testosterone include warnings about increased risk of heart attacks and stroke.[3][15][16] WP

Transgender men

To take advantage of its virilizing effects, testosterone, often shortened to T, is administered to transgender men and other transmasculine individuals as part of masculinizing hormone therapy, titrated to clinical effect with a "target level" of the average male's testosterone level.[17][18] WP

Women

Testosterone therapy is effective in the short-term for the treatment of hypoactive sexual desire disorder (HSDD) in women. However, its long-term safety is unclear. Because of a lack data to support its efficacy and safety, the Endocrine Society recommends against the routine use of testosterone in women to treat low androgen levels due to hypopituitarism, adrenal insufficiency, surgical removal of the ovaries, high-dose corticosteroid therapy, or other causes. Similarly, because of a lack of data to support its efficacy and safety, the Endocrine Society recommends against the use of testosterone in women to improve general well-being, to treat infertility, sexual dysfunction due to causes other than HSDD, or to improve cognitive, cardiovascular, metabolic, and/or bone health.[19] WP

A 2014 systematic review and meta-analysis of 35 studies consisting of over 5,000 postmenopausal women with normal adrenal gland function found that testosterone therapy was associated with significant improvement in a variety of domains of sexual function. These domains included frequency of sexual activity, orgasm, arousal, and sexual satisfaction, among others. Women who were menopausal due to ovariectomy showed significantly greater improvement in sexual function with testosterone relative to those who had normal menopause. In addition to beneficial effects on sexual function, testosterone was associated with unfavorable changes in blood lipids. These included decreased levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol, and increased levels of low-density lipoprotein (LDL) cholesterol. However, the changes were small in magnitude, and the long-term significance in relation to cardiovascular outcomes is uncertain. The changes were more pronounced with oral testosterone undecanoate than with parenteral routes, such as transdermal testosterone. Testosterone showed no significant effect on depressed mood anxiety, bone mineral density (BMD), or anthropomorphic measures like body weight or body mass index. Conversely, it was associated with a significant incidence of androgenic side effects, including acne and hirsutism (excessive facial/body hair growth). Other androgenic side effects, such as weight gain, pattern hair loss, and voice deepening, were also reported in some trials, but were excluded from analyses due to insufficient data. The overall quality of the evidence was rated as low and was considered to be inconclusive in certain areas, for instance on long-term safety.[20] WP

A subsequent 2017 systematic review and meta-analysis of studies including over 3,000 postmenopausal women with HSDD similarly found that short-term transdermal testosterone therapy was effective in improving multiple domains of sexual function. Androgenic adverse effects such as acne and hirsutism were significantly greater in incidence with testosterone therapy, whereas no significant differences in "increase in facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction to the patch, total adverse events, serious adverse events, reasons for withdrawal from the study, and the number of women who completed the study" were seen relative to controls.[21] WP

Although testosterone has been found to be effective at improving sexual function in postmenopausal women, the doses employed have been supraphysiological. In contrast to these high doses, there is little support for the notion that testosterone is a critical hormone for sexual desire and function in women under normal physiological circumstances. Low doses of testosterone resulting in physiological levels of testosterone (<50 ng/dL) have not been found to significantly increase sexual desire or function in women in most studies. Similarly, there appears to be little or no relationship between total or free testosterone levels in the normal physiological range and sexual desire in premenopausal women. Only high doses of testosterone resulting in supraphysiological levels of testosterone (>50 ng/dL) significantly increase sexual desire in women, with levels of testosterone of 80 to 150 ng/dL "slightly" increasing sex drive. In accordance, men experience sexual dysfunction at testosterone levels of below 300 ng/dL, and men that have levels of testosterone of approximately 200 ng/dL frequently experience such problems. The high doses of testosterone required to increase sexual desire in women may have a significant risk of masculinization with long-term therapy. For this reason, and due to the unknown health effects and safety of testosterone therapy, its use may be inappropriate. In 2003, the FDA rejected Intrinsa, a 300 μg/day testosterone patch for the treatment of sexual dysfunction in postmenopausal women. The reasons cited were limited efficacy (about one additional sexually satisfying event per month), concerns about safety and potential adverse effects with long-term therapy, and concerns about inappropriate off-label use. It appears that in women, rather than testosterone, estradiol may be the most important hormone involved in sexual desire, although data on the clinical use of estradiol to increase sexual desire in women is limited.[22–25] WP

There are no testosterone products approved for use in women in the United States and many other countries. There are approved testosterone products for women in Australia, where it is considered a drug of dependence, medicines that are subject to misuse and trafficking, and some European countries. Testosterone pellet implants are approved for use in postmenopausal women in the United Kingdom. Testosterone products for men can be used off-label in women in the United States. Alternatively, testosterone products for women are available from compounding pharmacies in the United States, although such products are unregulated and manufacturing quality is not ensured.[26–30] WP

Available forms

Testosterone has been marketed for use by oral, sublingual, buccal, intranasal, transdermal (patches), topical (gels), intramuscular (injection), and subcutaneous (implant) administration. It is provided unmodified and as a testosterone ester such as testosterone cypionate, testosterone enanthate, testosterone propionate, or testosterone undecanoate, which act as prodrugs of testosterone. The most common route of administration for testosterone is by intramuscular injection. However, it has been reported that AndroGel, a transdermal gel formulation of testosterone, has become the most popular form of testosterone in androgen replacement therapy for hypogonadism in the United States.[31][32] WP

Athletics

Testosterone is used as a form of doping among athletes with the intent to improve performance; accordingly, testosterone is listed on The Prohibited List of the World Anti-Doping Agency as an anabolic agent banned from competitive sports.[33] WP

After a series of scandals and publicity in the 1980s (such as Ben Johnson's improved performance at the 1988 Summer Olympics), prohibitions of AAS use were renewed or strengthened by many sports organizations. Testosterone and other AAS were designated a "controlled substance" by the United States Congress in 1990, with the Anabolic Steroid Control Act. Their use is seen as an issue in modern sport, particularly given the lengths to which athletes and professional laboratories go to in trying to conceal such use from sports regulators. Steroid use once again came into the spotlight as a result of Canadian professional wrestler Chris Benoit's double murder-suicide in 2007; however, there is no evidence implicating steroid use as a factor in the incident.[34] WP⚠ Wikipedia itself has flagged this text: citation needed.

Some female athletes may have naturally higher levels of testosterone than others, and may be asked to consent to sex verification and either surgery or drugs to decrease testosterone levels. This has proven contentious, with the Court of Arbitration for Sport suspending the IAAF policy due to insufficient evidence of a link between high androgen levels and improved athletic performance.[35][36][37] WP

Effects in the body and brain

The ARs are expressed widely throughout the body, including in the penis, testicles, epididymides, prostate gland, seminal vesicles, fat, skin, bone, bone marrow, muscle, larynx, heart, liver, kidneys, pituitary gland, hypothalamus, and elsewhere throughout the brain. Through activation of the ARs (as well as the mARs), testosterone has many effects, including the following:[31][38][39] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

• Promotes growth, function, and maintenance of the prostate gland, seminal vesicles, and penis during puberty and thereafter[31][38][39] WP
• Promotes growth and maintenance of muscles, particularly of the upper body[31][38][39] WP
• Causes subcutaneous fat to be deposited in a masculine pattern and decreases overall body fat[31][38][39] WP
• Suppresses breast development induced by estrogens, but can also still produce gynecomastia via excessive conversion into estradiol if levels are too high[31][38][39] WP
• Maintains skin health, integrity, appearance, and hydration and slows the rate of aging of the skin, but can also cause oily skin, acne, and seborrhea[31][38][39] WP
• Promotes the growth of facial and body hair, but can also cause scalp hair loss and hirsutism[31][38][39] WP
• Contributes to bone growth and causes broadening of the shoulders at puberty[31][38][39] WP
• Modulates liver protein synthesis, such as the production of sex hormone-binding globulin and many other proteins[31][38][39] WP
• Increases production of erythropoietin in the kidneys and thereby stimulates red blood cell production in bone marrow and elevates hematocrit[31][38][39] WP
• Exerts negative feedback on the hypothalamic–pituitary–gonadal axis by suppressing the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, thereby inhibiting gonadal sex hormone production as well as spermatogenesis and fertility[31][38][39] WP
• Regulates the vasomotor system and body temperature via the hypothalamus, thereby preventing hot flashes[31][38][39] WP
• Modulates brain function, with effects on mood, emotionality, aggression, and sexuality, as well as cognition and memory[31][38][39] WP
• Increases sex drive and erectile capacity and causes spontaneous erections and nocturnal emissions[31][38][39] WP
• Increases the risk of benign prostatic hyperplasia and accelerates the progression of prostate cancer[31][38][39] WP
• Decreases breast proliferation and the risk of breast cancer[31][38][39] WP

Usage

In the US in the 2000s, companies and figures in the popular media have heavily marketed notions of "andropause" as something parallel to menopause; these notions have been rejected by the medical community. Additionally, advertising from drug companies selling testosterone and human growth hormone, as well as dietary supplement companies selling all kinds of "boosters" for aging men, have emphasized the "need" of middle-aged or aging men for testosterone. There is a medical condition called late-onset hypogonadism; according to Thomas Perls and David J. Handelsman, writing in a 2015 editorial in the Journal of the American Geriatrics Society, it appears that this condition is overdiagnosed and overtreated. Perls and Handelsman note that in the US, "sales of testosterone increased from $324 million in 2002 to $2 billion in 2012, and the number of testosterone doses prescribed climbed from 100 million in 2007 to half a billion in 2012, not including the additional contributions from compounding pharmacies, Internet, and direct-to-patient clinic sales."[40][41][42] WP

Risks and side effects

Detection of abuse

A number of methods for detecting testosterone use by athletes have been employed, most based on a urine test. These include the testosterone/epitestosterone ratio (normally less than 6), the testosterone/luteinizing hormone ratio and the carbon-13/carbon-12 ratio (pharmaceutical testosterone contains less carbon-13 than endogenous testosterone). In some testing programs, an individual's own historical results may serve as a reference interval for interpretation of a suspicious finding. Another approach being investigated is the detection of the administered form of testosterone, usually an ester, in hair.[43–46] WP

Contraindications

Absolute contraindications of testosterone include prostate cancer, elevated hematocrit (>54%), uncontrolled congestive heart failure, various other cardiovascular diseases, and uncontrolled obstructive sleep apnea. Breast cancer is said by some sources to be an absolute contraindication of testosterone therapy, but androgens including testosterone have also actually been used to treat breast cancer. Relative contraindications of testosterone include elevated prostate-specific antigen (PSA) in men with a high risk of prostate cancer due to ethnicity or family history, severe lower urinary tract symptoms, and elevated hematocrit (>50%).[47][48] WP

Side effects

In February 2025, the US Food and Drug Administration (FDA) specified label changes for products containing testosterone. The changes include removing language from the boxed warning related to an increased risk of adverse cardiovascular outcomes and adding a new warning about increased blood pressure.[49] WP

Adverse effects may also include minor side effects such as oily skin, acne, and seborrhea, as well as loss of scalp hair, which may be prevented or reduced with 5α-reductase inhibitors. In women, testosterone can produce hirsutism (excessive facial/body hair growth), deepening of the voice, and other signs of virilization. Exogenous testosterone may cause suppression of spermatogenesis in men, leading to, in some cases, reversible infertility. Gynecomastia and breast tenderness may occur with high dosages of testosterone due to peripheral conversion of testosterone by aromatase into excessive amounts of the estrogen estradiol. Testosterone treatment, particularly in high dosages, can also be associated with mood changes, increased aggression, increased sex drive, spontaneous erections, and nocturnal emissions.[50–55] WP

Other side effects include increased hematocrit, which can require venipuncture in order to treat, and exacerbation of sleep apnea.[56] WP

The FDA stated in 2015 that neither the benefits nor the safety of testosterone have been established for low testosterone levels due to aging. The FDA has required that testosterone pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke. They have also required the label include concerns about abuse and dependence.[3][57] WP

Injectable forms of testosterone can cause a lung problem called pulmonary oil microembolism (POME). Symptoms of POME include cough, shortness of breath, tightening of the throat, chest pain, sweating, dizziness, and fainting. A postmarketing analysis by the manufacturer of Aveed (testosterone undeconate injection) found that POME occurred at a rate of less than 1% per injection per year for Aveed.[58][59][60] WP

Cardiovascular disease

Results from the TRAVERSE trial were submitted in 2023, concluding that there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.[49][61] WP

Adverse effects of testosterone supplementation may include increased cardiovascular events (including strokes and heart attacks) and deaths based on three peer-reviewed studies involving men taking testosterone replacement. In addition, an increase of 30% in deaths and heart attacks in older men has been reported. Due to an increased incidence of adverse cardiovascular events compared to a placebo group, a Testosterone in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee. On January 31, 2014, reports of strokes, heart attacks, and deaths in men taking FDA-approved testosterone-replacement led the FDA to announce that it would be investigating the issue. Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT). The FDA now requires warnings in the drug labeling of all approved testosterone products regarding deep vein thrombosis and pulmonary embolism.[62–69] WP

Up to the year 2010, studies had not shown any effect on the risk of death, prostate cancer or cardiovascular disease; more recent studies, however, do raise concerns. A 2013 study, published in the Journal of the American Medical Association, reported "the use of testosterone therapy was significantly associated with increased risk of adverse outcomes." The study began after a previous, randomized, clinical trial of testosterone therapy in men was stopped prematurely "due to adverse cardiovascular events raising concerns about testosterone therapy safety."[63][70][71][72] WP⚠ Wikipedia itself has flagged this text: when?.

However, when given to men with hypogonadism in the short- and medium-term, testosterone replacement therapy does not increase the risk of cardiovascular events (including strokes and heart attacks and other heart diseases). The long-term safety of the therapy is not known yet.[73][74] WP

Benign prostatic hyperplasia

Testosterone therapy for patients with late-onset hypogonadism, in addition to increasing risk of cardiovascular disease and prostate cancer, may exacerbate the risk factors associated with benign prostatic hyperplasia, a condition that involves the noncancerous enlargement of the prostate gland, which can lead to urinary symptoms.[75] WP

Prostate cancer

Testosterone in the presence of a slow-growing prostate cancer is assumed to increase its growth rate. However, the association between testosterone supplementation and the development of prostate cancer is unproven. Nevertheless, physicians are cautioned about the cancer risk associated with testosterone supplementation.[76][77] WP

Testosterone may accelerate pre-existing prostate cancer growth in individuals who have undergone androgen deprivation. It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy.[15][56] WP

Ethnic groups have different rates of prostate cancer. Differences in sex hormones, including testosterone, have been suggested as an explanation for these differences. This apparent paradox can be resolved by noting that prostate cancer is common. In autopsies, 80% of 80-year-old men have prostate cancer.[78][79] WP

Pregnancy and breastfeeding

Testosterone is contraindicated in pregnancy and not recommended during breastfeeding. Androgens like testosterone are teratogens and are known to cause fetal harm, such as producing virilization and ambiguous genitalia.[80] WP

Interactions

5α-reductase inhibitors

5α-Reductase inhibitors like finasteride and dutasteride can slightly increase circulating levels of testosterone by inhibiting its metabolism. However, these drugs do this via prevention of the conversion of testosterone into its more potent metabolite dihydrotestosterone (DHT), and this results in dramatically reduced circulating levels of DHT (which circulates at much lower relative concentrations). In addition, local levels of DHT in so-called androgenic (5α-reductase-expressing) tissues are also markedly reduced, and this can have a strong impact on certain effects of testosterone. For instance, growth of body and facial hair and penile growth induced by testosterone may be inhibited by 5α-reductase inhibitors, and this could be considered undesirable in the context of, for instance, puberty induction. On the other hand, 5α-reductase inhibitors may prevent or reduce adverse androgenic side effects of testosterone like scalp hair loss, oily skin, acne, and seborrhea. In addition to the prevention of testosterone conversion into DHT, 5α-reductase inhibitors also prevent the formation of neurosteroids like 3α-androstanediol from testosterone, and this may have neuropsychiatric consequences in some men.[32][81–85] WP

Aromatase inhibitors

Aromatase inhibitors like anastrozole prevent the conversion of testosterone into estradiol by aromatase. As only a small fraction of testosterone is converted into estradiol, this does not affect testosterone levels, but it can prevent estrogenic side effects like gynecomastia that can occur when testosterone is administered at relatively high dosages. However, estradiol exerts negative feedback on the hypothalamic–pituitary–gonadal axis and, for this reason, prevention of its formation can reduce this feedback and disinhibit gonadal production of testosterone, which in turn can increase levels of endogenous testosterone. Testosterone therapy is sometimes combined with an aromatase inhibitor for men with secondary hypogonadism who wish to conceive children with their partners.[32][86][87] WP

Cytochrome P450 inhibitors

Inhibitors and inducers of cytochrome P450 enzymes like CYP3A4 have been associated with little or no effect on circulating testosterone levels. WP⚠ Wikipedia itself has flagged this text: citation needed.

Antiandrogens and estrogens

Antiandrogens like cyproterone acetate, spironolactone, and bicalutamide can block the androgenic and anabolic effects of testosterone. Estrogens can reduce the effects of testosterone by increasing the hepatic production and in turn circulating levels of sex hormone-binding globulin (SHBG), a carrier protein that binds to and occupies androgens like testosterone and DHT, and thereby reducing free concentrations of these androgens.[88][89] WP

Pharmacology

Pharmacodynamics

Testosterone is a high affinity ligand for and agonist of the nuclear androgen receptor (AR). In addition, testosterone binds to and activates membrane androgen receptors (mARs) such as GPRC6A and ZIP9. Testosterone is also potentiated via transformation by 5α-reductase into the more potent androgen DHT in so-called androgenic tissues such as the prostate gland, seminal vesicles, skin, and hair follicles. In contrast to the case of testosterone, such potentiation occurs to a reduced extent or not at all with most synthetic AAS (as well as with DHT), and this is primarily responsible for the dissociation of anabolic and androgenic effects with these agents. In addition to DHT, testosterone is converted at a rate of approximately 0.3% into the estrogen estradiol via aromatase. This occurs in many tissues, especially adipose tissue, the liver, and the brain, but primarily in adipose tissue. Testosterone, after conversion into DHT, is also metabolized into 3α-androstanediol, a neurosteroid and potent positive allosteric modulator of the GABAA receptor, and 3β-androstanediol, a potent and preferential agonist of the ERβ. These metabolites, along with estradiol, may be involved in a number of the effects of testosterone in the brain, including its antidepressant, anxiolytic, stress-relieving, rewarding, and pro-sexual effects. Whereas testosterone produced both anabolic and androgenic effects, despite the lack of clear boundaries between these effects, as there is a great deal of mutual overlap between them, the relative potency of these effects exerted by testosterone can depend on various factors and is a topic of ongoing research.[90–95] WP

Pharmacokinetics

Testosterone can be taken by a variety of different routes of administration. These include oral, buccal, sublingual, intranasal, transdermal (gels, creams, patches), rectal suppositories), by intramuscular or subcutaneous injection (in oil or aqueous), and as a subcutaneous implant. The pharmacokinetics of testosterone, including its bioavailability, circulating testosterone levels, metabolism, biological half-life, and other parameters, differ by route of administration.[96] WP

Research

Depression

A 2018 meta-analysis concluded that testosterone treatment is associated with a modest reduction in depressive symptoms in men, especially at higher doses and in carefully selected populations. A 2014 meta-analysis found that testosterone improves mood, especially in middle-aged hypogonadal men with subthreshold depression, but shows limited effect in older or eugonadal men. A 2009 review found that testosterone had an antidepressant effect in men with depression, especially those with hypogonadism, HIV/AIDS, and in the elderly.[97][98][99] WP

Heart failure

Testosterone replacement can significantly improve exercise capacity, muscle strength and reduce QT intervals in men with chronic heart failure (CHF). Over the 3 to 6-month course of the studies reviewed, testosterone therapy appeared safe and generally effective, and (ruling out prostate cancer) the authors found no justification to absolutely restrict its use in men with CHF. A similar 2012 review also found increased exercise capacity and reasoned the benefits generlizable to women. However, both reviews advocate larger, longer term, randomized controlled trials.[100][101] WP

Male contraception

Testosterone, as esters such as testosterone undecanoate or testosterone buciclate, has been studied and promoted as a male contraceptive analogous to estrogen-based contraceptives in women. Otherwise considered an adverse effect of testosterone, reduced spermatogenesis can be further suppressed with the addition of a progestin such as norethisterone enanthate or levonorgestrel butanoate, improving the contraceptive effect.[102][103] WP

Anorgasmia

Testosterone is under development in a low-dose intranasal formulation for the treatment of anorgasmia in women.[104] WP

Miscellaneous

Testosterone therapy may improve the management of type 2 diabetes. Low testosterone has been associated with the development of Alzheimer's disease.[105][106][107] WP

Topical androgens like testosterone have been used and studied in the treatment of cellulite in women.[108] WP

History

History

Testosterone was first isolated and synthesized in 1935. Shortly thereafter, in 1937, testosterone first became commercially available as a pharmaceutical drug in the form of pellets and then in ester form for intramuscular injection as the relatively short-acting testosterone propionate. Methyltestosterone, one of the first synthetic AAS and orally active androgens, was introduced in 1935, but was associated with hepatotoxicity and eventually became largely medically obsolete. In the mid-1950s, the longer-acting testosterone esters testosterone enanthate and testosterone cypionate were introduced. They largely superseded testosterone propionate and became the major testosterone esters used medically for over half a century. In the 1970s, testosterone undecanoate was introduced for oral use in Europe, although intramuscular testosterone undecanoate had already been in use in China for several years. Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later (in the early to mid 2000s and 2014, respectively).[4][31][32][109–112] WP

The history of testosterone as a medication has been reviewed.[113–116] WP

Legal status

Generic names

Testosterone is the generic name of testosterone in English and Italian and the INN (International Nonproprietary Name), USAN (United States Adopted Name), USP (United States Pharmacopeia), BAN (British Approved Name), and DCIT (Denominazione Comune Italiana) of the drug, while testostérone is its French name and the DCF (Dénomination Commune Française). It is also referred to in Latin as testosteronum, in Spanish and Portuguese as testosterona, and in German, Dutch, and Russian and other Slavic languages as testosteron. The Cyrillic script of testosterone is тестостерон.[117–120] WP

Brand names

Testosterone is marketed under a large number of brand names throughout the world. Major brand names of testosterone and/or its esters include Andriol, Androderm, AndroGel, Axiron, Delatestryl, Depo-Testosterone, Intrinsa, Nebido, Omnadren, Primoteston, Sustanon, Testim, TestoGel, TestoPatch, Testoviron, and Tostran.[90][118] WP

United states

As of November 2016, unmodified (non-esterified) testosterone is available in the United States in the following formulations: WP

• Topical gels: AndroGel, Fortesta, Testim, Testosterone (generic) WP
• Topical solutions: Axiron, Testosterone (generic) WP
• Transdermal patches: Androderm, Testoderm (discontinued), Testoderm TTS (discontinued), Testosterone (generic) WP
• Intranasal gels: Natesto WP
• Buccal tablets: Striant WP
• Pellet implants: Testopel WP

And the following ester prodrugs of testosterone are available in the United States in oil solutions for intramuscular injection: WP

• Testosterone cypionate: Depo-Testosterone, Testosterone Cypionate (generic) WP
• Testosterone enanthate: Delatestryl, Xyosted (auto-injector), Testosterone Enanthate (generic) WP
• Testosterone propionate: Testosterone Propionate (generic) WP
• Testosterone undecanoate: Aveed WP

Unmodified testosterone was also formerly available for intramuscular injection but was discontinued. WP

Testosterone cypionate and testosterone enanthate were formerly available in combination with estradiol cypionate and estradiol valerate, respectively, under the brand names Depo-Testadiol and Ditate-DS, respectively, as oil solutions for intramuscular injection, but these formulations have been discontinued. WP

Unlike in Europe, Canada, and much of the rest of the world, oral testosterone undecanoate is not available in the United States. WP

Canada

As of November 2016, testosterone is available in Canada in the form of topical gels (AndroGel, Testim), topical solutions (Axiron), transdermal patches (Androderm), and intranasal gels (Natesto). Testosterone cypionate (Depo-Testosterone, Testosterone Cypionate (generic)), testosterone enanthate (Delatestryl, PMS-Testosterone Enanthate), and testosterone propionate (Testosterone Propionate (generic)) are available as oil solutions for intramuscular injection and testosterone undecanoate (Andriol, PMS-Testosterone, Taro-Testosterone) is available in the form of oral capsules. Testosterone buccal tablets and pellet implants do not appear to be available in Canada.[121] WP

Other countries

Testosterone and/or its esters are widely available in countries throughout the world in a variety of formulations.[118] WP

Legal status

Testosterone and its esters, along with other AAS, are prescription-only controlled substances in many countries throughout the world. In the United States, they are Schedule III drugs under the Controlled Substances Act, in Canada, they are Schedule IV drugs under the Controlled Drugs and Substances Act, and in the United Kingdom, they are Class C drugs under the Misuse of Drugs Act.[122][123] WP

Litigation

As of 2014, a number of lawsuits are underway against manufacturers of testosterone, alleging a significantly increased rate of stroke and heart attack in elderly men who use testosterone supplementation.[124] WP

Doping in sports

There are many known cases of doping in sports with testosterone and its esters by professional athletes. WP

Chemistry

Formula

C19H28O2 PC

CAS number

58-22-0 PC

Molar mass (g/mol)

288.4 PC

IUPAC name (computed by PubChem)

(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one PC

SMILES

C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C PC

InChIKey

MUMGGOZAMZWBJJ-DYKIIFRCSA-N PC

PubChem CID

6013

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Testosterone (monograph). November 17, 2025
2. Other List of Gender Dysphoria Medications (6 Compared)
3. Journal / agency Staff. Testosterone Products: Drug Safety Communication – FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke. March 3, 2015
4. Other Taylor WN. Anabolic Steroids and the Athlete. 2002
5. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
6. Journal / agency Desroches B, Kohn TP, Welliver C, Pastuszak AW. Testosterone therapy in the new era of Food and Drug Administration oversight. Translational Andrology and Urology. April 2016. doi:10.21037/tau.2016.03.13 · PMID 27141448 · PMC4837303
7. Other World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
8. Other Top 300 of 2023
9. Other Testosterone Drug Usage Statistics, United States, 2014 - 2023
10. Journal / agency Margo K, Winn R. Testosterone treatments: why, when, and how?. American Family Physician. May 2006. PMID 16719252
11. Journal / agency Myers JB, Meacham RB. Androgen replacement therapy in the aging male. Reviews in Urology. 2003. PMID 16985841 · PMC1508369
12. Journal / agency Qaseem A, Horwitch CA, Vijan S, Etxeandia-Ikobaltzeta I, Kansagara D. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. January 2020. doi:10.7326/M19-0882 · PMID 31905405
13. Other Parry NM. New Guideline for Testosterone Treatment in Men With 'Low T'. January 7, 2020
14. Journal / agency Sizar O, Leslie SW, Schwartz J. StatPearls. February 25, 2024. PMID 30422528
15. Journal / agency Testosterone and Aging: Clinical Research Directions. January 1, 2004. doi:10.17226/10852 · PMID 25009850
16. Journal / agency Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Jamrozik K, Flicker L. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. European Journal of Endocrinology. May 2007. doi:10.1530/EJE-06-0714 · PMID 17468195
17. Other Gender dysphoria – Treatment. May 21, 2012
18. Other Gorton RN, Buth J, Spade D. Medical Therapy and Health Maintenance for Transgender Men: A Guide For Health Care Providers
19. Journal / agency Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. Oct 2014. doi:10.1210/jc.2014-2260 · PMID 25279570
20. Journal / agency Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, Nabhan M, Firwana B, Altayar O, Prokop L, Montori VM, Murad MH. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2014. doi:10.1210/jc.2014-2262 · PMID 25279572 · PMC5393495
21. Journal / agency Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil. Steril. 2017. doi:10.1016/j.fertnstert.2016.10.028 · PMID 27916205
22. Journal / agency Cappelletti M, Wallen K. Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens. Horm Behav. February 2016. doi:10.1016/j.yhbeh.2015.11.003 · PMID 26589379 · PMC4720522
23. Journal / agency Reed BG, Bou Nemer L, Carr BR. Has testosterone passed the test in premenopausal women with low libido? A systematic review. Int J Women's Health. 2016. doi:10.2147/IJWH.S116212 · PMID 27785108 · PMC5066846
24. Journal / agency Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction. J Sex Med. March 2016. doi:10.1016/j.jsxm.2015.11.015 · PMID 26944462
25. Journal / agency Stone L. Sexual medicine: Transdermal oestrogen is effective. Nat Rev Urol. November 2017. doi:10.1038/nrurol.2017.152 · PMID 28895561
26. Other Pal L, Sayegh RA. Essentials of Menopause Management: A Case-Based Approach. January 21, 2017
27. Other Drugs of dependence and drug-dependent persons
28. Other Lobo RA, Kelsey J, Marcus R. Menopause: Biology and Pathobiology. May 22, 2000
29. Other Bagatell C, Bremner WJ. Androgens in Health and Disease. May 27, 2003
30. Journal / agency L'Hermite M. Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use. Climacteric. June 2017. doi:10.1080/13697137.2017.1285277 · PMID 28509626
31. Other Nieschlag E, Behre MH. Testosterone: Action - Deficiency - Substitution. December 6, 2012
32. Other Llewellyn W. Anabolics. 2011
33. Other The Prohibited List: S1. Anabolic Agents | List of Prohibited Substances and Methods. 2026
34. Other Anabolic Steroid Control Act. 1990
35. Other Karkazis K, Jordan-Young R. The Trouble With Too Much T. April 11, 2014
36. Other Fagan K. Katie Ledecky is crushing records, so why are we still worried about Caster Semenya?. August 13, 2016
37. Other Padawer R. The Humiliating Practice of Sex-Testing Female Athletes. June 28, 2016
38. Other Nieschlag E, Behre HM, Nieschlag S. Andrology: Male Reproductive Health and Dysfunction. January 13, 2010
39. Other Strauss JF, Barbieri RL, Gargiulo AR. Yen & Jaffe's Reproductive Endocrinology E-Book: Physiology, Pathophysiology, and Clinical Management. December 23, 2017
40. Other Male Menopause. April 8, 2016
41. Other Gorski D. "Low T": The triumph of marketing over science « Science-Based Medicine. November 25, 2013
42. Journal / agency Perls T, Handelsman DJ. Disease mongering of age-associated declines in testosterone and growth hormone levels. Journal of the American Geriatrics Society. April 2015. doi:10.1111/jgs.13391 · PMID 25809947
43. Journal / agency Strahm E, Emery C, Saugy M, Dvorak J, Saudan C. Detection of testosterone administration based on the carbon isotope ratio profiling of endogenous steroids: international reference populations of professional soccer players. British Journal of Sports Medicine. Dec 2009. doi:10.1136/bjsm.2009.058669 · PMID 19549614 · PMC2784500
44. Journal / agency Kicman AT, Cowan DA. Subject-based profiling for the detection of testosterone administration in sport. Drug Testing and Analysis. Jan 2009. doi:10.1002/dta.14 · PMID 20355155
45. Journal / agency Pozo OJ, Deventer K, Van Eenoo P, Rubens R, Delbeke FT. Quantification of testosterone undecanoate in human hair by liquid chromatography-tandem mass spectrometry. Biomedical Chromatography. Aug 2009. doi:10.1002/bmc.1199 · PMID 19353724
46. Other Baselt RC. Disposition of Toxic Drugs & Chemicals in Man. 2008
47. Other Clinical Urologic Endocrinology: Principles for Men's Health. October 19, 2012
48. Other Perry MC. The Chemotherapy Source Book. 2008
49. Journal / agency FDA issues class-wide labeling changes for testosterone products. February 28, 2025
50. Journal / agency Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. October 1990. doi:10.1016/0140-6736(90)92416-F · PMID 1977002
51. Journal / agency Rhoden EL, Morgentaler A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. International Journal of Impotence Research. February 2004. doi:10.1038/sj.ijir.3901154 · PMID 14963480
52. Journal / agency Yates WR. Testosterone in Psychiatry. Archives of General Psychiatry. 2000. doi:10.1001/archpsyc.57.2.155
53. Journal / agency Johnson JM, Nachtigall LB, Stern TA. The effect of testosterone levels on mood in men: a review. Psychosomatics. 2013. doi:10.1016/j.psym.2013.06.018 · PMID 24016385
54. Journal / agency Davidson JM, Kwan M, Greenleaf WJ. Hormonal replacement and sexuality in men. Clinics in Endocrinology and Metabolism. November 1982. doi:10.1016/s0300-595x(82)80003-0 · PMID 6814798
55. Other Bagatell C, Bremner WJ. Androgens in Health and Disease. May 27, 2003
56. Journal / agency Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. The Journal of Urology. Aug 2013. doi:10.1016/j.juro.2013.02.002 · PMID 23395803 · PMC4544840
57. Journal / agency Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement - Risks Associated With Abuse and Dependence. October 25, 2016
58. Other Testosterone Injection. August 2, 2020
59. Journal / agency Testosterone Injection. March 15, 2019
60. Journal / agency Pastuszak AW, Hu Y, Freid JD. Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis. Sexual Medicine. June 2020. doi:10.1016/j.esxm.2020.01.009 · PMID 32184081 · PMC7261689
61. Journal / agency Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England Journal of Medicine. July 2023. doi:10.1056/NEJMoa2215025 · PMID 37326322
62. Journal / agency Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS ONE. January 2014. doi:10.1371/journal.pone.0085805 · PMID 24489673 · PMC3905977
63. Journal / agency Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. Nov 2013. doi:10.1001/jama.2013.280386 · PMID 24193080
64. Journal / agency Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. The New England Journal of Medicine. July 8, 2010. doi:10.1056/NEJMoa1000485 · PMID 20592293 · PMC3440621
65. Journal / agency Staff. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. January 31, 2014
66. Other Tavernise S. F.D.A. Panel Backs Limits on Testosterone Drugs. September 17, 2014
67. Other Staff. FDA Panel To Review Testosterone Therapy Appropriateness and Safety. September 5, 2014
68. Journal / agency Staff. Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety And Risk Management Advisory Committee (DSARM AC) – FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT): 1. The appropriate indicated population for TRT, and 2. The potential for adverse cardiovascular outcomes associated with use of TRT. September 17, 2014
69. Journal / agency Staff. FDA adding general warning to testosterone products about potential for venous blood clots. June 19, 2014
70. Journal / agency Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings. Jan 2007. doi:10.4065/82.1.29 · PMID 17285783
71. Journal / agency Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism. Jun 2010. doi:10.1210/jc.2009-2575 · PMID 20525906
72. Journal / agency Testosterone Products: Drug Safety Communication – FDA Investigating Risk of Cardiovascular Events. January 31, 2014
73. Journal / agency Research provides reassurance about the safety of testosterone treatment. NIHR Evidence. February 6, 2023. doi:10.3310/nihrevidence_56696
74. Journal / agency Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder PJ, Ellenberg SS, Grossmann M, Travison TG, Gianatti EJ, van der Schouw YT, Emmelot-Vonk MH, Giltay EJ, Hackett G, Ramachandran S, Svartberg J, Hildreth KL, Groti Antonic K, Brock GB, Tenover JL, Tan HM, Kong CH, Tan WS, Marks LS, Ross RJ, Schwartz RS, Manson P, Roberts S, Andersen MS, Magnussen LV, Hernández R, Oliver N, Wu F, Dhillo WS, Bhattacharya S, Brazzelli M, Jayasena CN. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet. Healthy Longevity. June 2022. doi:10.1016/S2666-7568(22)00096-4 · PMID 35711614 · PMC9184259
75. Journal / agency Snyder P. Testosterone treatment of late-onset hypogonadism - benefits and risks. Rev Endocr Metab Disord. December 2022. doi:10.1007/s11154-022-09712-1 · PMID 35266057
76. Journal / agency Rhoden EL, Averbeck MA. Testosterone therapy and prostate carcinoma. Current Urology Reports. Nov 2009. doi:10.1007/s11934-009-0072-1 · PMID 19863857
77. Journal / agency Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. The Journal of Urology. Aug 2005. doi:10.1097/01.ju.0000165166.36280.60 · PMID 16006887
78. Journal / agency Calistro Alvarado L. Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men. American Journal of Human Biology. 2010. doi:10.1002/ajhb.21016 · PMID 20087895
79. Journal / agency Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. Nov 2004. doi:10.1002/cncr.20408 · PMID 15495199
80. Other Testosterone Pregnancy and Breastfeeding Warnings
81. Other Jameson JL, de Kretser DM, Marshall JC, De Groot JL. Endocrinology Adult and Pediatric: Reproductive Endocrinology. May 7, 2013
82. Other Blume-Peytavi U, Whiting DA, Trüeb RM. Hair Growth and Disorders. June 26, 2008
83. Other Bagatelle C, Bremner WJ. Androgens in Health and Disease. May 27, 2003
84. Other Baskin LS. Hypospadias and Genital Development. December 6, 2012
85. Other Neurosteroids
86. Journal / agency Simpson ER. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. September 2003. doi:10.1016/S0960-0760(03)00360-1 · PMID 14623515
87. Other Andrology: Male Reproductive Health and Dysfunction. 2009
88. Other Wecker L, Crespo L, Dunaway G, Faingold C, Watts S. Brody's Human Pharmacology. April 1, 2009
89. Other Partin AW, Wein AJ, Kavoussi LR, Peters CA. Campbell-Walsh Urology. October 23, 2015
90. Journal / agency Kicman AT. Pharmacology of anabolic steroids. British Journal of Pharmacology. June 2008. doi:10.1038/bjp.2008.165 · PMID 18500378 · PMC2439524
91. Other Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. October 14, 2012
92. Journal / agency Kohtz AS, Frye CA. Psychiatric Disorders. 2012. doi:10.1007/978-1-61779-458-2_26 · PMID 22231829
93. Journal / agency Handelsman DJ. Endotext [Internet]. January 2013. PMID 25905231
94. Journal / agency Čeponis J, Wang C, Swerdloff S, Liu PY. Thyroid Diseases. 2017. doi:10.1007/978-3-319-29456-8_11-1
95. Journal / agency Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002. doi:10.1210/rp.57.1.411 · PMID 12017555
96. Journal / agency Behre HM, Nieschlag E. Testosterone: Action, Deficiency, Substitution. July 26, 2012. doi:10.1017/CBO9781139003353.016
97. Journal / agency Breidenstein J, Miller R, Walther A. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019-01-01. doi:10.1001/jamapsychiatry.2018.2734 · PMID 30427999 · PMC6583468
98. Journal / agency Chibnall JT, Seo BW, Manepalli JN, Grossberg GT, Amanatkar HR. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Annals of Clinical Psychiatry. 2014. doi:10.1177/104012371402600103 · PMID 24501728
99. Journal / agency Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. Journal of Psychiatric Practice. July 2009. doi:10.1097/01.pra.0000358315.88931.fc · PMID 19625884
100. Journal / agency Wang W, Jiang T, Li C, Chen J, Cao K, Qi LW, Li P, Zhu W, Zhu B, Chen Y. Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. Journal of Thoracic Disease. May 2016. doi:10.21037/jtd.2016.03.39 · PMID 27162680 · PMC4842839
101. Journal / agency Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone Supplementation in Heart Failure: A Meta-Analysis. Circulation: Heart Failure. May 2012. doi:10.1161/CIRCHEARTFAILURE.111.965632 · PMID 22511747
102. Journal / agency Wang C, Festin MP, Swerdloff RS. Male Hormonal Contraception: Where Are We Now?. Current Obstetrics and Gynecology Reports. 2016. doi:10.1007/s13669-016-0140-8 · PMID 26949570 · PMC4762912
103. Journal / agency Chao JH, Page ST. The current state of male hormonal contraception. Pharmacology & Therapeutics. July 2016. doi:10.1016/j.pharmthera.2016.03.012 · PMID 27016468
104. Journal / agency Testosterone intranasal (low-dose)
105. Journal / agency Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. Journal of Andrology. 2009. doi:10.2164/jandrol.108.005751 · PMID 18772488
106. Journal / agency Pike CJ, Rosario ER, Nguyen TV. Androgens, aging, and Alzheimer's disease. Endocrine. Apr 2006. doi:10.1385/ENDO:29:2:233 · PMID 16785599
107. Journal / agency Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age-related testosterone depletion and the development of Alzheimer disease. JAMA. Sep 2004. doi:10.1001/jama.292.12.1431-b · PMID 15383512
108. Journal / agency Gruber CJ, Wieser F, Gruber IM, Ferlitsch K, Gruber DM, Huber JC. Current concepts in aesthetic endocrinology. Gynecol. Endocrinol. December 2002. doi:10.1080/gye.16.6.431.441 · PMID 12626029
109. Other Hoberman J. Testosterone Dreams: Rejuvenation, Aphrodisia, Doping. February 21, 2005
110. Other Mundy AR, Fitzpatrick J, Neal DE, George NJ. The Scientific Basis of Urology. July 26, 2010
111. Other Melmed S, Polonsky KS, Larsen PR. Williams Textbook of Endocrinology. November 11, 2015
112. Journal / agency Adis R&D Profile. Testosterone Undecanoate—Schering AG. Drugs. 2004. doi:10.2165/00126839-200405060-00012 · PMID 15563244
113. Journal / agency Nieschlag E, Nieschlag S. Testosterone. 2017. doi:10.1007/978-3-319-46086-4_1
114. Journal / agency Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. European Journal of Endocrinology. June 2019. doi:10.1530/EJE-19-0071 · PMID 30959485
115. Journal / agency Nieschlag E, Nieschlag S. Testosterone deficiency: a historical perspective. Asian Journal of Andrology. 2014. doi:10.4103/1008-682X.122358 · PMID 24435052 · PMC3955324
116. Journal / agency Morgentaler A, Traish A. The History of Testosterone and the Evolution of its Therapeutic Potential. Sexual Medicine Reviews. April 2020. doi:10.1016/j.sxmr.2018.03.002 · PMID 29661690
117. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. November 14, 2014
118. Other Testosterone - International
119. Other Index Nominum 2000: International Drug Directory. January 2000
120. Other Владимир Мюллер. Англо-русский словарь. Русско-английский словарь. 250 000 слов. April 15, 2016
121. Other Drug Product Database - Health Canada. March 18, 2010
122. Other Karch SB. Drug Abuse Handbook, Second Edition. December 21, 2006
123. Other Lilley LL, Snyder JS, Collins SR. Pharmacology for Canadian Health Care Practice. August 5, 2016
124. Other Harris A. Abbott Labs Sued by Five Men Claiming Androgel Injuries. February 5, 2014

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.